- 全部删除
您的购物车当前为空
Nanatinostat (CHR-3996)是一种具有口服利用度的HDAC抑制剂,对HDAC1/2/3的IC50=3~7 nM,对其他亚型的IC50则>200nM,还能够抑制肿瘤细胞增殖和诱导凋亡,可用于研究神经退行性疾病和癌症。

Nanatinostat (CHR-3996)是一种具有口服利用度的HDAC抑制剂,对HDAC1/2/3的IC50=3~7 nM,对其他亚型的IC50则>200nM,还能够抑制肿瘤细胞增殖和诱导凋亡,可用于研究神经退行性疾病和癌症。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 1,380 | In stock | |
| 5 mg | ¥ 3,150 | In stock | |
| 10 mg | ¥ 4,890 | In stock | |
| 25 mg | ¥ 7,470 | In stock | |
| 50 mg | ¥ 9,870 | In stock | |
| 100 mg | ¥ 13,500 | In stock | |
| 200 mg | ¥ 18,300 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 3,650 | In stock |
Nanatinostat 相关产品
| 产品描述 | Nanatinostat (CHR-3996) is an HDAC inhibitor with selectivity and oral bioavailability, with IC50 values of 3-7 nM for HDAC1/2/3 and >200 nM for other subtypes. Nanatinostat also inhibits tumour cell proliferation and induces apoptosis, for studying neurodegenerative diseases and cancer. |
| 靶点活性 | HDAC1:3 nM, HDAC5:200 nM, HDAC2:4 nM, HDAC3:7 nM, HDAC:8 nM, HDAC6:2100 nM |
| 体外活性 | 方法:Nanatinostat (CHR-3996) (30 mg/kg,口服)处理 |
| 体内活性 | 方法:Nanatinostat (CHR-3996) (0.0001-100μM)处理H929、KMS11、LP-1、MM1-S和RPMI-8828细胞,WST-1检测细胞增殖。 |
| 别名 | 奈替诺司他, CHR-3996, CHR3996 |
| 分子量 | 394.4 |
| 分子式 | C20H19FN6O2 |
| CAS No. | 1256448-47-1 |
| Smiles | N(CC1=NC2=C(C=C1)C=C(F)C=C2)[C@H]3[C@]4([C@@]3(CN(C4)C=5N=CC(C(NO)=O)=CN5)[H])[H] |
| 密度 | 1.51 g/cm3 (Predicted) |
| 存储 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 40 mg/mL (101.42 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.07 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容